This Pharma Distribution Stock Rises 49% in 1 Year: Thin Margins, Big Ambitions
- September 17, 2026
- Posted by: Harsh Piplani
- Category: Best Stocks
Entero Healthcare: CMP Rs 1,682.70 (17 Sep 2026), 1-year return approximately 49%, 52-week range Rs 944 to Rs 1,920, market cap around Rs 7,529 crore, Q1 FY27 EBITDA margin 5.15%.
Quick Answer
Entero Healthcare Solutions is the pharma distribution stock that returned approximately 49% over the year to 17 September 2026, rising from Rs 1,132.30 to Rs 1,682.70. The move came from a Q1 FY27 margin beat on 8 August 2026, a Rs 150 crore block purchase by a domestic fund house on 24 August 2026, and steady buying by mutual funds. The business remains a thin-margin, acquisition-led one, with a net margin near 2% and a trailing multiple well above the industry average.
This pharma distribution stock has risen approximately 49% in 1 year, from Rs 1,132.30 on 17 September 2025 to Rs 1,682.70 on 17 September 2026. That is a big return for a business that keeps two rupees of profit out of every hundred rupees of medicine it ships.
The company is Entero Healthcare Solutions Ltd (NSE: ENTERO), one of India’s three largest distributors of pharmaceutical and surgical products by revenue. The Entero Healthcare share price drifted for most of the year, bottomed at Rs 944 in late December 2025, then ran hard from August 2026. Almost the entire gain in this pharma distribution stock came in about six weeks.
Click Here – Get Free Investment Predictions
How Much Has This Pharma Distribution Stock Returned in 1 Year?
Approximately 49%. The Entero Healthcare share price closed at Rs 1,132.30 on 17 September 2025 and traded at Rs 1,682.70 on 17 September 2026, a gain of 48.6%. There has been no split or bonus since listing, so the return on this pharma distribution stock is pure price appreciation.
| Period | From (Rs) | To (Rs) | Return |
|---|---|---|---|
| 1 Month | 1,401.60 | 1,682.70 | 20.1% |
| 6 Months | 1,026.60 | 1,682.70 | 63.9% |
| 1 Year | 1,132.30 | 1,682.70 | 48.6% |
| Since IPO price | 1,258.00 | 1,682.70 | 33.8% |
| Since listing-day close | 1,149.55 | 1,682.70 | 46.4% |
Three-year and five-year figures do not exist. The company listed on 16 February 2024 at Rs 1,258 and closed day one at Rs 1,149.55, so an IPO holder has earned roughly 33.8% in two and a half years, well short of the one-year headline for this pharma distribution stock.
On 17 September 2026 the Entero Healthcare share price fell approximately 2.8% from Rs 1,731.80. The 52-week range is Rs 944 to Rs 1,920, so this pharma distribution stock sits roughly 12% below its record high. It ranked among the better performers on a screen of NSE small-cap stocks by 1-year return, dated 17 September 2026.
Why Did This Pharma Distribution Stock Rise 49% in 1 Year?
Three dated events did the work: June quarter results on 8 August 2026, a large block purchase on 24 August 2026, and FY26 results with acquisition approvals on 25 May 2026. Before August this pharma distribution stock went nowhere.
Q1 FY27 Results on 8 August 2026 Hit the Margin Target Early
Entero Healthcare reported June 2026 quarter revenue of Rs 1,940.50 crore, up 38.23%. The EBITDA margin reached 5.00% against 3.57%, matching full-year FY27 guidance two quarters early. Consolidated profit after tax rose about 72% to roughly Rs 52 crore, of which Rs 38.16 crore was attributable to shareholders.
The split mattered more than the total. Organic revenue grew 17.8% as reported and 19.6% like-for-like against pharmaceutical market growth of about 13.8%, and gross margin improved 147 basis points to 11.4%. For a pharma distribution stock, proving the base business can outgrow the market without buying it is the argument.
A Rs 150 Crore Block Deal on 24 August 2026
On 24 August 2026 two funds run by a domestic fund house bought 10,88,500 shares, or 2.50% of equity, at Rs 1,377.80 each, worth about Rs 150.04 crore. The seller was Prasid Uno Family Trust, a pre-IPO holder with 10.45%. The Entero Healthcare share price jumped 5.31% that day to Rs 1,611.10.
The pharma distribution stock then gained 30.42% over the seven sessions to 28 August 2026 and touched a record Rs 1,920 on 7 September 2026. A high-conviction buyer taking a block from a departing early investor removed an overhang and gave the market a reason to re-price this pharma distribution stock.
FY26 Results and Two Acquisitions Approved on 25 May 2026
The board approved FY26 results on 25 May 2026: revenue of about Rs 6,591 crore, up 29.3%, and net profit near Rs 145.84 crore. The same day it cleared two Telangana distributors, Vishal Surgicals of Khammam for up to Rs 6.3 crore and Vishal Surgicals and Medicals of Warangal for up to Rs 2.91 crore, both due by 31 December 2026. That is how this pharma distribution stock grows: small cheques, many of them.
Domestic Funds Replaced Departing Foreign Investors
Domestic institutional holding rose from 10.18% in June 2025 to 15.48% in June 2026 while foreign holding fell from 17.20% to 4.37%. Hybrid, flexi-cap, multi-cap and healthcare schemes now hold sizeable positions, and steady domestic buying into a small free float explains much of the move in this pharma distribution stock.
Check the Univest Screener for Live Fundamentals of High-Return Stocks
Entero Healthcare Financials: Big Revenue, Thin Margins
Revenue has grown in each of the past five quarters and the operating margin has widened from 3.98% to 5.15%. The company turns over nearly Rs 2,000 crore a quarter and keeps around Rs 100 crore as EBITDA. That ratio is the number that defines a pharma distribution stock.
| Quarter | Revenue (Rs Cr) | EBITDA (Rs Cr) | Operating Margin | Net Profit (Rs Cr) | Net Margin |
|---|---|---|---|---|---|
| Jun 2025 | 1,409.65 | 55.90 | 3.98% | 30.23 | 1.98% |
| Sep 2025 | 1,575.74 | 66.85 | 4.26% | 36.60 | 2.01% |
| Dec 2025 | 1,711.13 | 72.39 | 3.76% | 33.88 | 1.88% |
| Mar 2026 | 1,913.94 | 90.05 | 4.71% | 45.13 | 1.47% |
| Jun 2026 | 1,943.51 | 100.00 | 5.15% | 52.05 | 1.97% |
Yearly, the story repeats. FY24 revenue was Rs 3,936.72 crore with net profit of Rs 39.80 crore. FY26 delivered Rs 6,610.45 crore of revenue, Rs 277.01 crore of EBITDA and Rs 145.84 crore of net profit, a 4.20% operating margin and a 2.21% net margin.
Profitability is recent. This pharma distribution stock lost about Rs 11.10 crore in FY23. Operating cash flow was negative in FY23, FY24 and FY25 and turned positive at Rs 96.20 crore only in FY26, while capital expenditure rose to Rs 67.54 crore.
FY26 equity was Rs 1,752.55 crore against assets of Rs 3,600.26 crore, debt-to-equity near 0.31, book value roughly Rs 386.51 per share. Reported return on equity was approximately 6.81% and return on capital employed around 10.5%, though management quoted 21.1% on its own measure. That gap matters before buying any pharma distribution stock on a returns argument.
The Acquisition-Led Model Behind This Pharma Distribution Stock
Incorporated in 2018, Entero Healthcare grew by buying regional distributors rather than building. In the June 2026 quarter it ran 138 distribution centres across 19 states, served more than 72,000 retail pharmacies and 2,300 hospitals, and handled over 83,400 SKUs. Inorganic growth contributed 20.4% of Q1 FY27 revenue growth against 17.8% organic. Working capital days improved from 66 to 61, which in a pharma distribution stock works like a margin expansion.
The cost is complexity. Many acquired entities are held at less than full ownership, which is why consolidated profit of about Rs 52 crore in Q1 FY27 became Rs 38.16 crore attributable to shareholders. This pharma distribution stock trades near 45 times trailing consolidated profit against an industry average of about 37, and above 60 times on attributable profit. Price to book is about 4.48 times.
Management has reaffirmed FY27 guidance of roughly 23% revenue growth at a 5% EBITDA margin, with the medical technology segment, heading towards Rs 1,000 crore of revenue, as the main margin lift.
Shareholding: Who Owns This Pharma Distribution Stock?
Promoter holding has been frozen near 52.42% for five quarters. The largest single holder is a healthcare-focused private equity fund with 38.00%, then founder Prabhat Agrawal at 9.26% and Prem Sethi at 5.15%. Promoters declared no encumbrance for FY26, so no pledge sits against this pharma distribution stock.
| Quarter | Promoters | FII | DII | Public |
|---|---|---|---|---|
| Jun 2025 | 52.42% | 17.20% | 10.18% | 20.19% |
| Sep 2025 | 52.42% | 14.67% | 9.65% | 23.26% |
| Dec 2025 | 52.42% | 5.14% | 16.42% | 26.02% |
| Mar 2026 | 52.42% | 4.03% | 16.62% | 26.93% |
| Jun 2026 | 52.40% | 4.37% | 15.48% | 27.75% |
December 2025 is where the handover happened, foreign holding collapsing from 14.67% to 5.14% and domestic institutions jumping from 9.65% to 16.42%. The 38.00% private equity stake sits inside the promoter block of this pharma distribution stock, not the foreign column.
Risks in This Pharma Distribution Stock
The margin structure comes first in any pharma distribution stock. A net margin near 2% means a 100 basis point slip in gross margin, a price control order, or one big customer defaulting can erase a real slice of annual profit. Pricing power against manufacturers or organised pharmacy chains is minimal.
Acquisition integration is second. Growth depends on continuously finding, pricing and absorbing family-run distributors, each adding goodwill, minority interests and new systems. FY26 total liabilities almost doubled to Rs 1,847.72 crore, and rising interest cost on acquisition borrowings is already a flagged pressure point.
Third is liquidity and volatility. At a market capitalisation of about Rs 7,529 crore this pharma distribution stock is a small cap that moved 30.42% in seven sessions in August 2026 and fell 2.8% on 17 September 2026. A single 2.50% block moved the price more than 5% in a day, which cuts both ways when a large holder sells.
Fourth is the residual overhang. Prasid Uno Family Trust still held around 7.95% after the August sale, and the 38.00% private equity holder will want an exit eventually. Foreign holding fell from 22.20% in December 2024 to 4.37%, and that selling took this pharma distribution stock to Rs 944 before the recovery.
Fifth is cash and compliance. There has never been a dividend, operating cash flow was negative for three straight years before FY26, and a GST penalty of Rs 12.92 lakh hit subsidiary ACE Cardiopathy in September 2026 over an e-invoice. Trivial in size, it shows the oversight burden inside one pharma distribution stock.
Download the Univest iOS App or Univest Android App to track the Entero Healthcare share price live
Entero Healthcare Share: Analyst View
Coverage on this pharma distribution stock is thin and has lagged the rally. A compiled consensus of four analysts carried an average target of Rs 1,614, a range of Rs 1,500 to Rs 1,800, and four buy ratings. That average sits below the traded price of Rs 1,682.70, so the market has outrun published estimates.
In August 2025 the same group averaged Rs 1,497 on an FY26 earnings estimate of Rs 35.23, and a foreign brokerage upgraded the pharma distribution stock on 8 January 2026 with a target of Rs 1,320. Reported FY26 diluted earnings per share was Rs 26.40, below that estimate.
Entero Healthcare Share Price Target
No verified Entero Healthcare share price target has been published since the August 2026 rally. The available Entero Healthcare share price target range of Rs 1,500 to Rs 1,800 was set before the Q1 FY27 margin beat, so any figure quoted today should be checked for its date.
Without current estimates, the levels that matter for this pharma distribution stock are the record high of Rs 1,920 from 7 September 2026 as resistance and the August breakout zone near Rs 1,400 as support. Annualising the June 2026 quarter gives roughly Rs 35 of earnings per share, putting the stock at about 48 times that run rate.
Other Stocks to Track From the Same Return Screen
Beyond this pharma distribution stock, a screen of NSE small-cap stocks ranked by 1-year return also includes related names such as Suven Life Sciences with a 1-year return of 49.94%, Neuland Labs at 41.50% and Balaji Amines at 41.75%.
Among the names covered from that screen, MTAR Technologies returned 396.53% over one year. Readers can compare this pharma distribution stock with the Nifty 50 benchmark and track each of these names on Univest before making any decision.
Conclusion
This pharma distribution stock has delivered approximately 49% in one year, but the rally is six weeks old and rests on one strong quarter and one block purchase. The business is improving, with the operating margin up from 3.98% to 5.15% and organic growth ahead of the pharmaceutical market.
The economics have not. A net margin near 2%, a three-year profit record, no dividend and a growth engine that needs a steady supply of acquisitions leave little room for error at 45 times trailing earnings. Track the September quarter margin and whether domestic funds keep buying this pharma distribution stock, and speak to a SEBI-registered adviser before acting.
Disclaimer: Data and figures in this article are sourced from publicly available information and may or may not be accurate. Please verify all data independently before making any investment decision. Past returns do not guarantee future returns. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
Which pharma distribution stock rose 49% in 1 year?
Ans. Entero Healthcare Solutions Ltd (NSE: ENTERO) is the pharma distribution stock that gained approximately 49% between 17 September 2025 and 17 September 2026, from Rs 1,132.30 to Rs 1,682.70. It is among India’s three largest healthcare product distributors.
Why did the Entero Healthcare share price rise so sharply in August 2026?
Ans. Two events did most of it. Q1 FY27 results on 8 August 2026 showed a 5.00% EBITDA margin, hitting the full-year target early, and on 24 August 2026 two funds bought 2.50% of the company for Rs 150.04 crore. The pharma distribution stock gained 30.42% over the next seven sessions.
What were Entero Healthcare Q1 FY27 results?
Ans. Revenue was Rs 1,940.50 crore in the June 2026 quarter, up 38.23%, with an EBITDA margin of 5.00% against 3.57%. Consolidated profit after tax rose about 72% to Rs 52 crore, of which Rs 38.16 crore was attributable to shareholders.
What is the Entero Healthcare share price target?
Ans. No verified Entero Healthcare share price target has been published since the August 2026 rally. The most recent consensus of four analysts averaged Rs 1,614, in a range of Rs 1,500 to Rs 1,800, below the traded price of Rs 1,682.70, and it predates the Q1 FY27 margin beat.
What is the 52-week high and low of Entero Healthcare?
Ans. The 52-week high is Rs 1,920, touched on 7 September 2026, and the low is Rs 944, made in late December 2025. The Entero Healthcare share price was Rs 1,682.70 on 17 September 2026, about 12% below the high.
Why are the margins of this pharma distribution stock so thin?
Ans. A pharma distribution stock sits between manufacturers and pharmacies with little pricing power on either side, so volume drives the business. Entero Healthcare reported a gross margin of 11.4% and a net margin of 1.97% in Q1 FY27, and an FY26 net margin of 2.21%.
Have foreign investors sold out of Entero Healthcare?
Ans. Yes, foreign institutional holding fell from 22.20% in December 2024 to 4.37% in June 2026. Domestic institutions went the other way, from 10.18% to 15.48% in a year, so this pharma distribution stock has changed hands to domestic funds.
Is this pharma distribution stock risky for a small investor?
Ans. It carries real risk. A market capitalisation of about Rs 7,529 crore makes this pharma distribution stock a small cap that can move 30% in seven sessions, the net margin is near 2%, profitability is three years old, and growth depends on acquisitions. Advice from a SEBI-registered adviser is sensible.
